☰

Marco A. Goicochea, Ph.D. - Publications

Affiliations: 
2011 Molecular Microbiology and Immunology University of Maryland School of Medicine, Baltimore, MD, United States 
Area:
Immunology, Virology Biology
Tree Info Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Zapata JC, Goicochea M, Nadai Y, Eyzaguirre LM, Carr JK, Tallon LJ, Sadzewicz L, Myers G, Fraser CM, Su Q, Djavani M, Lukashevich IS, Salvato MS. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate. Journal of Virology. 88: 3058-66. PMID 24335292 DOI: 10.1128/Jvi.03035-13  0.686
2014 Goicochea M, Nata T, Gallo R, Cheng H, Tagaya Y. HBZ RNA may promote cell survival against clastogenic damages and thereby contributes to the development of leukemic ATL cells Retrovirology. 11: 1-1. DOI: 10.1186/1742-4690-11-S1-O56  0.309
2013 Zapata JC, Poonia B, Bryant J, Davis H, Ateh E, George L, Crasta O, Zhang Y, Slezak T, Jaing C, Pauza CD, Goicochea M, Moshkoff D, Lukashevich IS, Salvato MS. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virology Journal. 10: 52. PMID 23402317 DOI: 10.1186/1743-422X-10-52  0.687
2012 Goicochea MA, Zapata JC, Bryant J, Davis H, Salvato MS, Lukashevich IS. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine. 30: 1445-52. PMID 22234266 DOI: 10.1016/J.Vaccine.2011.12.134  0.679
2011 Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R, Brasky K, Patterson J, Goicochea M, Bryant J, Salvato MS, Lukashevich IS. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. 29: 1248-57. PMID 21145373 DOI: 10.1016/J.Vaccine.2010.11.079  0.655
2008 Lukashevich IS, Carrion R, Salvato MS, Mansfield K, Brasky K, Zapata J, Cairo C, Goicochea M, Hoosien GE, Ticer A, Bryant J, Davis H, Hammamieh R, Mayda M, Jett M, et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine. 26: 5246-54. PMID 18692539 DOI: 10.1016/J.Vaccine.2008.07.057  0.702
2008 Lukashevich IS, Zapata JC, Goicochea M, Carrion R, Patterson JL, Brasky K, Mansfield K, Salvato MS. Safety and Efficacy of ML29 Reassortant Lassa Fever Vaccine in Non-Human Primates International Journal of Infectious Diseases. 12. DOI: 10.1016/J.Ijid.2008.05.684  0.661
2006 Sun L, DeMasi L, Lafferty M, Goicochea M, Lu W, Garzino-Demo A. Retrovirology. 3: S77. DOI: 10.1186/1742-4690-3-S1-S77  0.317
Show low-probability matches.